Evaluation of microbial and vancomycin treatments in ulcerative colitis in murine models
PLOS ONE · 2023
DOI: 10.1371/journal.pone.0285613 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von Nihal Hasan und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Immunology, Tongji Hospital, Tongji Medical College, Huazhong University of Sciences and Technology, Wuhan, People's Republic …. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Colitis. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Natural Science Foundation of heilongjiang province, Fundamental Research Funds for the Central Universities.
Abstract (Originalsprache)
Background
Despite the number of available therapies for ulcerative colitis (UC), severe side effects and high cost has limited their clinical application. Thus, finding new alternative strategies with minimal side effects is inevitable. Therefore, this study aimed to compare the effectiveness of different therapeutic approaches in DSS-induced colitis.
Methods
Firstly, we designed oral bio-therapeutic products, Live Bacterial Products (LBP), which include a mixture of fecal bacteria strains isolated from healthy mice and prepared by microencapsulation and freeze-dried techniques. Then we investigated the efficiency of 7 days of freeze-dried FMT, LBP, and vancomycin treatments in DSS-induced colitis. Secondly, we compared the effect of 15 days of microbial therapies (freeze-dried powder of FMT and LBP microcapsules) and seven days of oral vancomycin on the severity of colitis in mice. Furthermore, the levels of IL-1β and TNF-α were measured in serum by ELISA, and the fecal microbiota diversity was analyzed by high-throughput sequencing for all mice groups.
Results
After seven days of treatments, our results indicated that oral vancomycin reduced the severity of DSS-induced colitis in mice, where weight gain and a decrease in IL-1 β and TNF-α levels were observed in the vancomycin group compared with other treatment groups. While after two weeks of treatment, the LBP microcapsules were able to reduce the severity of colitis. And at the end of the treatment period, weight gain and a decrease in the DAI scores and the levels of IL-1β and TNF-α were noted in the LBP treatment group compared to other treatment groups. By high-throughput sequencing of the 16S rRNA gene, our results showed that while the microcapsules LBP treatment increased the fecal microbial diversity, after vancomycin therapy, most of the fecal microbiota genera and operational taxonomic units (OTUs) were depleted.
Conclusion
Our results concluded that treatment duration and preparation methods affect the microbial therapies’ efficiency in UC. Furthermore, this study highlighted the negative consequences of oral vancomycin administration on gut health that should be known before using this medication.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Clinical Immunology, Tongji Hospital, Tongji Medical College, Huazhong University of Sciences and Technology, Wuhan, People's Republic of China.
- Faculty of Health Science, Al-Baath University, Homs, Syria.
- Department of Microbiology, Northeast Forestry University, Harbin, Heilongjiang, People's Republic of China.
ORCID-Profile: Hongyi Yang
Förderung
- the Natural Science Foundation of heilongjiang province
- Fundamental Research Funds for the Central Universities
Zitieren
APA
Hasan, N., & Yang, H. (2023). Evaluation of microbial and vancomycin treatments in ulcerative colitis in murine models. PLOS ONE. https://doi.org/10.1371/journal.pone.0285613
Vancouver
Hasan N, Yang H. Evaluation of microbial and vancomycin treatments in ulcerative colitis in murine models. PLOS ONE. 2023. doi:10.1371/journal.pone.0285613
BibTeX
@article{Hasan2023,
author = {Hasan, Nihal and Yang, Hongyi},
title = {Evaluation of microbial and vancomycin treatments in ulcerative colitis in murine models},
journal = {PLOS ONE},
year = {2023},
doi = {10.1371/journal.pone.0285613}
}
EUVIMED